The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, sponsored by the GOG, investigating the combination of ribociclib and letrozole in patients with recurrent low-grade serous ovarian cancer (LGSOC…
Philadelphia, PA, USA, March 25, 2023, The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, ...